I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am more cautious about ZYME now.

After decades of antipsychotic drugs, a new FDA-approved treatment for schizophrenia targets a different brain system—with ...